🚀 VC round data is live in beta, check it out!
Immatics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Immatics and similar public comparables like Daewoong Pharmaceutical, Chengdu Kanghua, Day One Biopharmaceutical, TOWA Pharmaceutical and more.
Immatics Overview
About Immatics
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Founded
2020
HQ
Employees
680
Website
Sectors
Financials (LTM)
EV
$850M
Immatics Financials
Immatics reported last 12-month revenue of $53M and negative EBITDA of ($205M).
In the same LTM period, Immatics generated $53M in gross profit, ($205M) in EBITDA losses, and had net loss of ($231M).
Revenue (LTM)
Immatics P&L
In the most recent fiscal year, Immatics reported revenue of $56M and EBITDA of ($196M).
Immatics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $53M | XXX | $56M | XXX | XXX | XXX |
| Gross Profit | $53M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($205M) | XXX | ($196M) | XXX | XXX | XXX |
| EBITDA Margin | (384%) | XXX | (351%) | XXX | XXX | XXX |
| EBIT Margin | (416%) | XXX | (374%) | XXX | XXX | XXX |
| Net Profit | ($231M) | XXX | ($226M) | XXX | XXX | XXX |
| Net Margin | (433%) | XXX | (404%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Immatics Stock Performance
Immatics has current market cap of $1B, and enterprise value of $850M.
Market Cap Evolution
Immatics' stock price is $9.99.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $850M | $1B | 0.0% | XXX | XXX | XXX | $-1.69 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialImmatics Valuation Multiples
Immatics trades at 15.9x EV/Revenue multiple, and (4.1x) EV/EBITDA.
EV / Revenue (LTM)
Immatics Financial Valuation Multiples
As of March 18, 2026, Immatics has market cap of $1B and EV of $850M.
Equity research analysts estimate Immatics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Immatics has a P/E ratio of (5.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $850M | XXX | $850M | XXX | XXX | XXX |
| EV/Revenue | 15.9x | XXX | 15.2x | XXX | XXX | XXX |
| EV/EBITDA | (4.1x) | XXX | (4.3x) | XXX | XXX | XXX |
| EV/EBIT | (3.8x) | XXX | (4.1x) | XXX | XXX | XXX |
| EV/Gross Profit | 15.9x | XXX | — | XXX | XXX | XXX |
| P/E | (5.8x) | XXX | (5.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Immatics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Immatics Margins & Growth Rates
Immatics' revenue in the last 12 month declined by (14%).
Immatics' revenue per employee in the last FY averaged $0.1M.
Immatics' rule of 40 is (398%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Immatics' rule of X is (419%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Immatics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (14%) | XXX | (22%) | XXX | XXX | XXX |
| EBITDA Margin | (384%) | XXX | (351%) | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (398%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (419%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 105% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 405% | XXX | 378% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 473% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Immatics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Daewoong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Chengdu Kanghua | XXX | XXX | XXX | XXX | XXX | XXX |
| Day One Biopharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| TOWA Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Youcare Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immatics M&A Activity
Immatics acquired XXX companies to date.
Last acquisition by Immatics was on XXXXXXXX, XXXXX. Immatics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Immatics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialImmatics Investment Activity
Immatics invested in XXX companies to date.
Immatics made its latest investment on XXXXXXXX, XXXXX. Immatics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Immatics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Immatics
| When was Immatics founded? | Immatics was founded in 2020. |
| Where is Immatics headquartered? | Immatics is headquartered in United States. |
| How many employees does Immatics have? | As of today, Immatics has over 680 employees. |
| Who is the CEO of Immatics? | Immatics' CEO is Harpreet Singh. |
| Is Immatics publicly listed? | Yes, Immatics is a public company listed on Nasdaq. |
| What is the stock symbol of Immatics? | Immatics trades under IMTX ticker. |
| When did Immatics go public? | Immatics went public in 2020. |
| Who are competitors of Immatics? | Immatics main competitors are Daewoong Pharmaceutical, Chengdu Kanghua, Day One Biopharmaceutical, TOWA Pharmaceutical. |
| What is the current market cap of Immatics? | Immatics' current market cap is $1B. |
| What is the current revenue of Immatics? | Immatics' last 12 months revenue is $53M. |
| What is the current revenue growth of Immatics? | Immatics revenue growth (NTM/LTM) is (14%). |
| What is the current EV/Revenue multiple of Immatics? | Current revenue multiple of Immatics is 15.9x. |
| Is Immatics profitable? | No, Immatics is not profitable. |
| What is the current EBITDA of Immatics? | Immatics has negative EBITDA and is not profitable. |
| What is Immatics' EBITDA margin? | Immatics' last 12 months EBITDA margin is (384%). |
| What is the current EV/EBITDA multiple of Immatics? | Current EBITDA multiple of Immatics is (4.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.